Evaxion’s AI technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients in the EVX-01 Phase 1 clinical trial Efficient Network Management: A Dive into Auvik Network Management’s Robust Features
In today’s fast-paced digital world, efficient and effective network management has become more important than…
Evaxion’s AI technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients in the EVX-01 Phase 1 clinical trial
The clinical trial of the personalized cancer vaccine EVX-01 met its primary endpoints of safety…
Janssen Presents Longer-Term Talquetamab Follow-Up Data Showing Overall Response Rates of More Than 70 Percent in Heavily Pretreated Patients with Multiple Myeloma
Additional long-term data from the TRiMM-2 study in patients receiving talquetamab and DARZALEX® (daratumumab) subcutaneous (SC)…
Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data…
Janssen Presents First Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients with Relapsed or Refractory Multiple Myeloma
BEERSE, BELGIUM, June 03, 2023 (GLOBE NEWSWIRE) — The Janssen Pharmaceutical Companies of Johnson &…
Cogent Biosciences Announces Positive Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST)
– Data presented at ASCO annual meeting demonstrate 55% Disease Control Rate (DCR) in heavily…
Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Updated data from ongoing IGNYTE anti-PD1 failed melanoma cohort shows RP1 combined with nivolumab continues…
NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023
– Met Primary Endpoint with 63.4% Median Reduction in LDL-C (p<0.0001) – – 87.1% of Patients Treated…
Mountain Valley Pipeline To Proceed
Enactment of Federal Legislation to Raise U.S. Debt Limit Ratifies and Expedites Approvals, Declares Project…
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of SentinelOne, Inc. (S) on Behalf of Investors
LOS ANGELES–(BUSINESS WIRE)–$S—Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm,…
Exai Bio Presents New Multi-Cancer Early Detection Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
Findings in over 3,000 subjects demonstrate highly sensitive and specific detection of multiple cancers at…
Affimed Presents AFM24 Monotherapy Data in Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology and Provides Strategic Update on AFM24 Development Plan
Data update from AFM24-101 phase 1/2 monotherapy study includes 15 patients from the EGFR mutant…
Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
Long Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrate Potential of Allogeneic CD19…
Elicio Therapeutics Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at the ASCO Annual Meeting
ELI-002 was shown to be well-tolerated with no dose limiting toxicity or cytokine release syndrome…
Apexigen Announces Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma Presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
– Marked increases in overall survival observed across soft tissue sarcoma patients – – Demonstrated…
Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
Early on-treatment ctDNA reduction in stable disease patients treated with KIMMTRAK was associated with longer…
Massive Bio and The Oncology Institute (TOI) Forge Partnership to Revolutionize Cancer Care and AI-enabled Cancer Research
NEW YORK–(BUSINESS WIRE)–Massive Bio, a leader in leveraging artificial intelligence and concierge services to empower…
Atlas Global Announces Changes to Canadian Operations
CHATHAM, ONTARIO and TEL-AVIV, ISRAEL, June 02, 2023 (GLOBE NEWSWIRE) — Atlas Global Brands Inc….
loanDepot Makes Executive Changes and Streamlines Organization
Changes in line with Vision 2025 strategy David Hayes named Chief Financial Officer IRVINE, Calif.–(BUSINESS…
loanDepot Makes Executive Changes and Streamlines Organization
Changes in line with Vision 2025 strategy David Hayes named Chief Financial Officer IRVINE, Calif.–(BUSINESS…
Delaware Investments National Municipal Income Fund Announces Revised Fund Adoption Date
PHILADELPHIA–(BUSINESS WIRE)–Today, Delaware Investments National Municipal Income Fund (the “Fund”), a New York Stock Exchange…